PROCTER & GAMBLE HEALTH | PANACEA BIOTECH | PROCTER & GAMBLE HEALTH/ PANACEA BIOTECH |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.4 | -60.5 | - | View Chart |
P/BV | x | 10.5 | 0.9 | 1,201.1% | View Chart |
Dividend Yield | % | 2.0 | 0.0 | - |
PROCTER & GAMBLE HEALTH PANACEA BIOTECH |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
PANACEA BIOTECH Mar-23 |
PROCTER & GAMBLE HEALTH/ PANACEA BIOTECH |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 191 | 2,804.1% | |
Low | Rs | 3,883 | 107 | 3,623.9% | |
Sales per share (Unadj.) | Rs | 740.7 | 75.1 | 986.4% | |
Earnings per share (Unadj.) | Rs | 138.2 | -5.5 | -2,509.1% | |
Cash flow per share (Unadj.) | Rs | 155.2 | 0.9 | 17,671.5% | |
Dividends per share (Unadj.) | Rs | 95.00 | 0 | - | |
Avg Dividend yield | % | 2.1 | 0 | - | |
Book value per share (Unadj.) | Rs | 447.6 | 137.7 | 325.0% | |
Shares outstanding (eoy) | m | 16.60 | 61.25 | 27.1% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 2.0 | 314.1% | |
Avg P/E ratio | x | 33.5 | -27.1 | -123.5% | |
P/CF ratio (eoy) | x | 29.8 | 170.0 | 17.5% | |
Price / Book Value ratio | x | 10.3 | 1.1 | 953.3% | |
Dividend payout | % | 68.7 | 0 | - | |
Avg Mkt Cap | Rs m | 76,761 | 9,142 | 839.7% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 1,265 | 163.0% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 4,599 | 267.3% | |
Other income | Rs m | 184 | 517 | 35.6% | |
Total revenues | Rs m | 12,480 | 5,116 | 243.9% | |
Gross profit | Rs m | 3,247 | 47 | 6,905.1% | |
Depreciation | Rs m | 281 | 391 | 71.8% | |
Interest | Rs m | 8 | 44 | 17.4% | |
Profit before tax | Rs m | 3,142 | 128 | 2,453.7% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 466 | 182.0% | |
Profit after tax | Rs m | 2,295 | -337 | -680.0% | |
Gross profit margin | % | 26.4 | 1.0 | 2,582.9% | |
Effective tax rate | % | 27.0 | 363.5 | 7.4% | |
Net profit margin | % | 18.7 | -7.3 | -254.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 5,623 | 208.3% | |
Current liabilities | Rs m | 6,791 | 3,297 | 205.9% | |
Net working cap to sales | % | 40.0 | 50.6 | 79.2% | |
Current ratio | x | 1.7 | 1.7 | 101.1% | |
Inventory Days | Days | 263 | 59 | 447.6% | |
Debtors Days | Days | 343 | 48 | 720.3% | |
Net fixed assets | Rs m | 10,617 | 7,028 | 151.1% | |
Share capital | Rs m | 166 | 61 | 271.0% | |
"Free" reserves | Rs m | 7,265 | 8,375 | 86.7% | |
Net worth | Rs m | 7,431 | 8,436 | 88.1% | |
Long term debt | Rs m | 0 | 202 | 0.0% | |
Total assets | Rs m | 22,330 | 12,712 | 175.7% | |
Interest coverage | x | 409.1 | 3.9 | 10,526.4% | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.4 | 152.2% | |
Return on assets | % | 10.3 | -2.3 | -447.2% | |
Return on equity | % | 30.9 | -4.0 | -772.0% | |
Return on capital | % | 42.4 | 2.0 | 2,123.5% | |
Exports to sales | % | 0 | 43.3 | 0.0% | |
Imports to sales | % | 13.1 | 24.4 | 53.4% | |
Exports (fob) | Rs m | NA | 1,992 | 0.0% | |
Imports (cif) | Rs m | 1,605 | 1,124 | 142.9% | |
Fx inflow | Rs m | 1,465 | 1,992 | 73.5% | |
Fx outflow | Rs m | 1,605 | 1,191 | 134.8% | |
Net fx | Rs m | -140 | 801 | -17.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | -4,225 | -55.9% | |
From Investments | Rs m | -215 | 4,303 | -5.0% | |
From Financial Activity | Rs m | -985 | -184 | 535.9% | |
Net Cashflow | Rs m | 1,160 | -105 | -1,105.3% |
Indian Promoters | % | 0.0 | 73.6 | - | |
Foreign collaborators | % | 51.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 20.3 | 1.0 | 2,132.6% | |
FIIs | % | 7.6 | 0.3 | 2,923.1% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 26.4 | 182.4% | |
Shareholders | 56,730 | 47,091 | 120.5% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PROCTER & GAMBLE HEALTH With: SUN PHARMA DIVIS LABORATORIES CIPLA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | Panacea Biotech | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.69% | -2.47% | 1.18% |
1-Month | -7.59% | -20.61% | -0.75% |
1-Year | -3.15% | 10.92% | 61.82% |
3-Year CAGR | -9.16% | -12.48% | 18.16% |
5-Year CAGR | 5.72% | -10.11% | 19.79% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the Panacea Biotech share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of Panacea Biotech the stake stands at 73.6%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of Panacea Biotech.
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
Panacea Biotech paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of Panacea Biotech.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.